INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $783.7 billion and impressive revenue growth of 32% in the last twelve months, has announced that its drug Omvoh (mirikizumab-mrkz) has shown sustained efficacy in Crohn’s disease patients over two years of continuous treatment. The VIVID-2 study results revealed that 92.9% of patients who were in clinical remission after the first year remained so after the second year. The study findings were presented at the Crohn’s and Colitis Congress in San Francisco. According to InvestingPro analysis, Eli Lilly is currently trading above its Fair Value, reflecting strong market confidence in its innovative drug pipeline.
Omvoh, which targets the interleukin-23p19 (IL-23p19) protein involved in intestinal inflammation, is the first IL-23p19 antagonist to demonstrate multi-year efficacy and safety for Crohn’s disease and ulcerative colitis. The drug was approved by the FDA in January 2025 for treating moderately to severely active Crohn’s disease in adults and has been approved in 44 countries for ulcerative colitis. With an industry-leading gross profit margin of 81.3%, Eli Lilly demonstrates strong operational efficiency in bringing innovative treatments to market.
The VIVID-2 study also showed that 87.6% of patients maintained their endoscopic response, which indicates visible healing of the intestinal lining. Additionally, 78.6% of patients in endoscopic remission at one year remained in remission after two years. The safety profile of Omvoh was consistent with previous findings, with 6.8% of patients reporting serious adverse events and 0.8% discontinuing treatment due to adverse events during the second year.
Dr. Edward Barnes from the University of North Carolina at Chapel Hill highlighted the importance of these results for healthcare providers whose patients have not found success with other therapies or lost efficacy with their current treatment. Eli Lilly’s senior vice president of immunology development, Dr. Mark Genovese, emphasized the significance of these findings in setting a high bar for long-term treatment response in inflammatory bowel disease.
Omvoh is also being studied in ongoing trials for Crohn’s disease and ulcerative colitis in both pediatric and adult patients, including a Phase 4 real-world evidence study. The drug’s approval and sustained success mark a significant advance in the treatment options available for individuals living with these chronic inflammatory conditions. The information is based on a press release statement from Eli Lilly and Company. For deeper insights into Eli Lilly’s financial health and growth prospects, InvestingPro subscribers have access to 15+ additional ProTips and comprehensive analysis through the Pro Research Report, helping investors make informed decisions about this pharmaceutical leader’s potential.
In other recent news, Eli Lilly has been in the spotlight with several research firms maintaining a positive outlook on the pharmaceutical giant. Bernstein reiterated an Outperform rating for Eli Lilly, with a focus on the company’s weight loss treatment, CagriSema. The firm noted an interesting pattern where patients with a lower dose of CagriSema experienced higher efficacy, attributing this to patients’ lower body mass index rather than the dosage itself.
Erste Group upgraded Eli Lilly from Hold to Buy, highlighting the company’s significant sales growth expected this year and a promising pipeline of potential successes. The firm’s analysts are optimistic about Eli Lilly’s future market performance, particularly due to the stability of prices for key products like Mounjaro and Zebound.
Truist Securities reaffirmed its Buy rating and increased its price target for Eli Lilly, noting positive growth trends for the company’s product, Zepbound. The firm also highlighted the overall growth trend for another Eli Lilly product, Mounjaro, within the broader diabetes GLP-1 market.
Meanwhile, Leerink Partners maintained an Outperform rating on Tectonic Therapeutics, despite concerns raised by the recent termination of a study by Eli Lilly that could impact Tectonic’s TX45, a drug in development for pulmonary hypertension. The firm awaits further clarity from Eli Lilly and commentary from Tectonic’s management on the matter. These developments underline the competitive but growing market for pharmaceutical treatments, with Eli Lilly poised to capitalize on these trends.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.